Connect with us

Hi, what are you looking for?

Stock

After-hours movers: HP Inc., Dell Technologies, Workday and more

After-Hours Stock Movers:

HP Inc. (NYSE:HPQ) fell 7.5% after it issued lackluster guidance. For fiscal 2025, HP estimates non-GAAP diluted net EPS to be in the range of $3.45 to $3.75, about in-line with consensus.

Dell Technologies (NYSE:DELL) fell 6% despite beating estimates for third quarter EPS and revenue. Revenue was $24.4 billion, up 10% year over year. Diluted earnings per share was $1.58, and non-GAAP diluted earnings per share was $2.15, up 16% and 14% year over year, respectively.

Autodesk (NASDAQ:ADSK) fell 7.7% despite beating estimates and raising guidance. Third quarter total revenue increased 11% to $1.57 billion.

Workday (NASDAQ:WDAY) fell 8% despite beating third quarter results, after it issued disappointing guidance. It sees Q4 subscription revenue of $2.025 billion, slightly below consensus of $2.04 billion.

CrowdStrike (NASDAQ:CRWD) fell 2.1% after beating third quarter results. Total revenue was $1,010.2 million, a 29% increase, compared to $786.0 million in the third quarter of fiscal 2024. Subscription revenue was $962.7 million, a 31% increase, compared to $733.5 million in the third quarter of fiscal 2024.

Urban Outfitters (NASDAQ:URBN) rose 5% after it published strong quarterly EPS and revenue. Total Company net sales for the three months ended October 31, 2024, increased 6.3% to a record $1.36 billion.

Nordstrom (NYSE:JWN) fell 1% despite beating estimates for its third quarter. Total Company net sales increased 4.6 percent and comparable sales increased 4.0 percent compared with the same period in fiscal 2023.

Ambarella (NASDAQ:AMBA) surged 25% after results beat the average analyst estimate and it issued strong guidance for the final quarter of the year. Revenue for the third quarter of fiscal 2025 was $82.7 million, up 63% from $50.6 million in the same period in fiscal 2024.

PTC Therapeutics (NASDAQ:PTCT) fell 13% after its Phase 2 placebo-controlled CardinALS study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis.

This post appeared first on investing.com

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.






    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like

    Editor's Pick

    Former president Donald Trump and his allies have filed hundreds of lawsuits, with more to come, seeking to tighten voting rules or disqualify voters....

    Economy

    LONDON (Reuters) – Bank of England interest rate-setter Megan Greene said she still believed the central bank should take a cautious approach to cutting...

    Editor's Pick

    Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

    Latest News

    Tunisians voted Sunday in an election expected to grant President Kais Saied a second term, as his most prominent detractors, including one of the candidates challenging...

    Disclaimer: beneficialinvestmentnow.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2024 beneficialinvestmentnow.com